Cipla vs Lupin: Which Stock Should You Track

August 6, 2026
Posted by: Ankit Jaiswal
Category: News

Cipla MCap Rs 1,17,138 Cr, PE 34.91x, ROE 11.27%, D/E 0.02. Lupin MCap Rs 1,08,638 Cr, PE 20.29x, ROE 23.76%, D/E 0.29.

Cipla vs Lupin is a comparison mid-to-large pharma investors look up when evaluating two of India’s leading pharmaceutical companies with strong US generic businesses and branded Indian formulations. Cipla is a Mumbai-based company known for its respiratory inhalers, anti-infective drugs and US generic filings, while Lupin is a Mumbai-based pharma company with strong cardiology and CNS branded prescriptions in India, a significant US generics business and a growing dermatology pipeline.

This Cipla vs Lupin article covers reach and market position, key products, latest declared results and stock valuation. The Cipla vs Lupin data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Table of Contents

Cipla vs Lupin: Reach and Market Position

On the Cipla side of the Cipla vs Lupin comparison, Cipla sells respiratory drugs, anti-infectives, oncology and hospital critical care products in India and generics in the US, South Africa and Europe. Market capitalisation is Rs 1,17,138 Cr.

Click Here – Get Free Investment Predictions

On the Lupin side of the Cipla vs Lupin comparison, Lupin sells branded cardiology, CNS, anti-infective and diabetes prescriptions in India and generics in the US, Europe and rest of world. Market capitalisation is Rs 1,08,638 Cr.

Cipla vs Lupin: Key Products and Business Mix

In the Cipla vs Lupin product comparison, Cipla offers: Cipla makes inhalers (Seroflo, Asthalin), anti-infectives, oncology drugs and US generics including inhaler biosimilars. P/E is 34.91x, ROE 11.27 percent, near-zero debt at 0.02.

For Lupin in this Cipla vs Lupin breakdown: Lupin makes Tonact (atorvastatin), Gluconorm (metformin), Suprax (cefixime) in India and complex generics in the US. P/E is 20.29x, ROE 23.76 percent, debt to equity 0.29.

Cipla vs Lupin: Latest Results

The Cipla vs Lupin results for Cipla: Cipla has a market cap of Rs 1,17,138 Cr and P/E of 34.91x. ROE is 11.27 percent with near-zero debt. Dividend yield is 0.90 percent.

The Cipla vs Lupin results for Lupin: Lupin has a market cap of Rs 1,08,638 Cr and P/E of 20.29x, significantly cheaper than Cipla. ROE is 23.76 percent — materially higher. Dividend yield is 0.76 percent.

Compare Cipla and Lupin Fundamentals on the Univest Screener

Cipla vs Lupin: Stock and Valuation

The Cipla vs Lupin stock comparison uses the latest available market data from Groww. Investors tracking Cipla vs Lupin should verify current prices on NSE or BSE before trading.

Cipla trades at a market cap of Rs 1,17,138 Cr and P/E of 34.91x with ROE of 11.27 percent. Lupin trades at Rs 1,08,638 Cr market cap and P/E of 20.29x — significantly cheaper — with a much higher ROE of 23.76 percent. Lupin’s higher ROE reflects its improving US generic and India branded mix.

Cipla vs Lupin: Quick Comparison Table

The Cipla vs Lupin comparison table below summarises the key metrics covered in this article side by side.

Parameter	Cipla	Lupin
Sector	Mid-large pharma: inhalers, anti-infective, US generics	Mid-large pharma: cardiology, CNS, complex US generics
Market Cap	Rs 1,17,138 Cr	Rs 1,08,638 Cr
P/E Ratio	34.91x	20.29x
ROE	11.27%	23.76%
Debt to Equity	0.02	0.29
Dividend Yield	0.90%	0.76%
Key India products	Seroflo, Asthalin respiratory inhalers	Tonact, Gluconorm, Suprax branded prescriptions
US strategy	Inhaler biosimilars and complex generics	Complex generics, specialty dermatology pipeline

Conclusion

The Cipla vs Lupin comparison above covers the key data points on reach, products, results and valuation. Cipla vs Lupin are two similarly sized mid-large pharma companies at very different valuations. Lupin is significantly cheaper with a higher ROE of 23.76 percent, while Cipla commands a premium for its inhaler franchise and US respiratory pipeline. Investors should review USFDA compliance, US pipeline approvals and India brand growth and consult a SEBI-registered advisor before investing.

Download the Univest iOS App or Univest Android App to track Cipla and Lupin live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information, including company results filings and exchange data, and are current as of the time of writing. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What is the main difference between Cipla and Lupin?

Ans. Cipla is known for its respiratory inhaler drugs and US generic inhalers. Lupin has strong branded cardiovascular and CNS drugs in India and a complex generics and dermatology pipeline in the US.

Which company has the higher ROE?

Ans. Lupin has an ROE of 23.76 percent, significantly higher than Cipla at 11.27 percent.

Which stock trades at a lower P/E?

Ans. Lupin trades at 20.29x trailing earnings, significantly cheaper than Cipla at 34.91x.

What is Cipla’s inhaler strategy?

Ans. Cipla is developing inhaler biosimilars and complex generic inhalers including FDA-approved versions of Advair Diskus and other branded respiratory drugs for the US market.

Why does Cipla trade at a premium to Lupin?

Ans. Cipla’s respiratory inhaler franchise commands a premium as inhalers are complex drug delivery devices with higher barriers to generic entry and potentially higher margins in the US.

What risks apply to pharma companies?

Ans. Both face risk from US FDA warning letters, generic pricing erosion, USFDA inspection observations and competition in key therapeutic segments.

Should I invest in Cipla or Lupin?

Ans. Lupin is cheaper with a higher ROE. Cipla has the premium inhaler franchise. Review USFDA compliance and pipeline approvals and consult a SEBI-registered advisor before investing.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.